These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35936010)

  • 21. Tumour necrosis factor receptor I blockade shows that TNF-dependent and TNF-independent mechanisms synergise in TNF receptor associated periodic syndrome.
    Fairclough LC; Stoop AA; Negm OH; Radford PM; Tighe PJ; Todd I
    Eur J Immunol; 2015 Oct; 45(10):2937-44. PubMed ID: 26202849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes.
    Todd I; Radford PM; Daffa N; Bainbridge SE; Powell RJ; Tighe PJ
    Arthritis Rheum; 2007 Aug; 56(8):2765-73. PubMed ID: 17665435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression profile in TNF receptor-associated periodic syndrome reveals constitutively enhanced pathways and new players in the underlying inflammation.
    Borghini S; Ferrera D; Prigione I; Fiore M; Ferraris C; Mirisola V; Amaro AA; Gueli I; Zammataro L; Gattorno M; Pfeffer U; Ceccherini I
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S121-S128. PubMed ID: 27310036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway.
    Greco E; Aita A; Galozzi P; Gava A; Sfriso P; Negm OH; Tighe P; Caso F; Navaglia F; Dazzo E; De Bortoli M; Rampazzo A; Obici L; Donadei S; Merlini G; Plebani M; Todd I; Basso D; Punzi L
    Arthritis Res Ther; 2015 Apr; 17(1):93. PubMed ID: 25888769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: a case report and review of the literature.
    Chen YJ; Yu HH; Yang YH; Lau YL; Lee WI; Chiang BL
    J Microbiol Immunol Infect; 2014 Dec; 47(6):550-4. PubMed ID: 22921805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome.
    Pucino V; Lucherini OM; Perna F; Obici L; Merlini G; Cattalini M; La Torre F; Maggio MC; Lepore MT; Magnotti F; Galgani M; Galeazzi M; Marone G; De Rosa V; Talarico R; Cantarini L; Matarese G
    J Leukoc Biol; 2016 May; 99(5):761-9. PubMed ID: 26598380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment.
    Stojanov S; Dejaco C; Lohse P; Huss K; Duftner C; Belohradsky BH; Herold M; Schirmer M
    Ann Rheum Dis; 2008 Sep; 67(9):1292-8. PubMed ID: 18180277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor necrosis factor receptor-associated periodic syndrome as a model linking autophagy and inflammation in protein aggregation diseases.
    Bachetti T; Ceccherini I
    J Mol Med (Berl); 2014 Jun; 92(6):583-94. PubMed ID: 24706103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion.
    Turner MD; Chaudhry A; Nedjai B
    Biosci Rep; 2012 Apr; 32(2):105-12. PubMed ID: 22115362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS).
    Bulua AC; Simon A; Maddipati R; Pelletier M; Park H; Kim KY; Sack MN; Kastner DL; Siegel RM
    J Exp Med; 2011 Mar; 208(3):519-33. PubMed ID: 21282379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overlap syndrome between Familial Mediterranean fever and tumor necrosis factor receptor-associated periodic syndrome in a lupus patient.
    Nonaka F; Migita K; Iwasaki K; Shimizu T; Kawakami A; Yasunami M; Eguchi K
    Tohoku J Exp Med; 2014 Jun; 233(2):73-7. PubMed ID: 24835548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour.
    Todd I; Radford PM; Draper-Morgan KA; McIntosh R; Bainbridge S; Dickinson P; Jamhawi L; Sansaridis M; Huggins ML; Tighe PJ; Powell RJ
    Immunology; 2004 Sep; 113(1):65-79. PubMed ID: 15312137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The tumour necrosis factor receptor-associated periodic syndrome: current concepts.
    Stojanov S; McDermott MF
    Expert Rev Mol Med; 2005 Oct; 7(22):1-18. PubMed ID: 16216134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel TNFRSF1A gene mutation in a patient with tumor necrosis factor receptor-associated periodic syndrome.
    Khabazi A; Maralani M; Andalib S; Sakhinia E
    Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):175-177. PubMed ID: 27793577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature.
    Cantarini L; Rigante D; Lucherini OM; Cimaz R; Laghi Pasini F; Baldari CT; Benucci M; Simonini G; Di Sabatino V; Brizi MG; Galeazzi M
    Int J Immunopathol Pharmacol; 2010; 23(3):701-7. PubMed ID: 20943039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) are hypersensitive to Toll-like receptor 9 stimulation.
    Negm OH; Singh S; Abduljabbar W; Hamed MR; Radford P; McDermott EM; Drewe E; Fairclough L; Todd I; Tighe PJ
    Clin Exp Immunol; 2019 Sep; 197(3):352-360. PubMed ID: 31009059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics.
    Inoue M; Tsuji Y; Yoshimine C; Enomoto S; Morita Y; Osaki N; Kunishige M; Miki M; Amano S; Yamashita K; Kamada H; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2020 Jul; 295(28):9379-9391. PubMed ID: 32398258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2.
    Pircher J; Merkle M; Wörnle M; Ribeiro A; Czermak T; Stampnik Y; Mannell H; Niemeyer M; Vielhauer V; Krötz F
    Arthritis Res Ther; 2012 Oct; 14(5):R225. PubMed ID: 23079185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tumor necrosis receptor associated periodic syndrome (TRAPS): State of the art].
    Georgin-Lavialle S; Kone-Paut I; Delaleu J; Sarrabay G; Grateau G; Touitou I; Hentgen V
    Rev Med Interne; 2018 Apr; 39(4):256-264. PubMed ID: 29525418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular and clinical spectrum of four pedigrees of TRAPS in Greece: results from a national referral center.
    Nezos A; Argyropoulou OD; Klinaki E; Marketos N; Karagianni P; Eliopoulos E; Vlachoyiannopoulos P; Maritsi DN; Tzioufas AG
    Rheumatology (Oxford); 2020 Jun; 59(6):1241-1246. PubMed ID: 31562507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.